Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (12)	4/5/2001 12:10:08 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 1840

Irrespective of breadth, this patent is too valuable not to be challenged. But if this patent is at its core about discovering the anti-cancer effects of Mab EGFr blockade in combination with chemo/rad, and with the presumption of validity, it will be tough to beat. Can't wait to read it. Will be very interesting anyway. A high-noon fight over the equivalence of functionally coincident but compositionally diverse Mabs could be as fascinating to watch as the epo arguments. Wilder